JP2015506961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506961A5 JP2015506961A5 JP2014555801A JP2014555801A JP2015506961A5 JP 2015506961 A5 JP2015506961 A5 JP 2015506961A5 JP 2014555801 A JP2014555801 A JP 2014555801A JP 2014555801 A JP2014555801 A JP 2014555801A JP 2015506961 A5 JP2015506961 A5 JP 2015506961A5
- Authority
- JP
- Japan
- Prior art keywords
- renal cell
- cell carcinoma
- optionally
- therapeutic agent
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 24
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 8
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims 5
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims 4
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 4
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 claims 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 3
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 3
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 3
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 3
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 3
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 3
- 229960003005 axitinib Drugs 0.000 claims 3
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960005167 everolimus Drugs 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 229960000639 pazopanib Drugs 0.000 claims 3
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 3
- 229960003787 sorafenib Drugs 0.000 claims 3
- 229960001796 sunitinib Drugs 0.000 claims 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 3
- 229960000235 temsirolimus Drugs 0.000 claims 3
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 3
- 229960000940 tivozanib Drugs 0.000 claims 3
- 229960000241 vandetanib Drugs 0.000 claims 3
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 3
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims 2
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 claims 2
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 claims 2
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 claims 2
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 claims 2
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102100020873 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 101000799194 Homo sapiens Serine/threonine-protein kinase receptor R3 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000047644 human ACVRL1 Human genes 0.000 claims 1
- 102000052974 human BMP10 Human genes 0.000 claims 1
- 102000046041 human GDF2 Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593864P | 2012-02-02 | 2012-02-02 | |
| US61/593,864 | 2012-02-02 | ||
| US201261597124P | 2012-02-09 | 2012-02-09 | |
| US61/597,124 | 2012-02-09 | ||
| PCT/US2013/024510 WO2013116781A1 (en) | 2012-02-02 | 2013-02-01 | Alk1 antagonists and their uses in treating renal cell carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015506961A JP2015506961A (ja) | 2015-03-05 |
| JP2015506961A5 true JP2015506961A5 (enExample) | 2016-03-17 |
Family
ID=48903082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555801A Pending JP2015506961A (ja) | 2012-02-02 | 2013-02-01 | Ａｌｋ１アンタゴニストおよび腎細胞癌の治療におけるその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130202594A1 (enExample) |
| EP (1) | EP2809335A4 (enExample) |
| JP (1) | JP2015506961A (enExample) |
| KR (1) | KR20140123558A (enExample) |
| CN (1) | CN104321070A (enExample) |
| AU (1) | AU2013214779A1 (enExample) |
| BR (1) | BR112014019151A2 (enExample) |
| CA (1) | CA2863188A1 (enExample) |
| MX (1) | MX2014009277A (enExample) |
| RU (1) | RU2633638C2 (enExample) |
| WO (1) | WO2013116781A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
| WO2008057461A2 (en) | 2006-11-02 | 2008-05-15 | Acceleron Pharma, Inc. | Alk1 receptor and ligand antagonists and uses thereof |
| US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| WO2015147908A1 (en) * | 2014-03-28 | 2015-10-01 | Acceleron Pharma, Inc. | Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer |
| JP2016036322A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | 血管新生因子と結合するキメラタンパク質 |
| US20180042998A1 (en) * | 2015-03-10 | 2018-02-15 | University Of Massachusetts | Targeting gdf6 and bmp signaling for anti-melanoma therapy |
| CA2982237A1 (en) | 2015-06-05 | 2016-12-08 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor |
| CN106994181A (zh) * | 2017-03-10 | 2017-08-01 | 上海交通大学医学院附属第九人民医院 | Bmp9在制备延缓肝纤维化药物中的应用 |
| IL322309A (en) | 2017-05-24 | 2025-09-01 | Novartis Ag | IL2 antibody grafted proteins and methods of use in cancer treatment |
| WO2019173482A1 (en) * | 2018-03-06 | 2019-09-12 | Sanford Burnham Prebys Medical Discovery Institute | 4-aminoquinoline compounds for the treatment of angiogenesis |
| AU2024252640A1 (en) | 2023-04-07 | 2025-10-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8529014D0 (en) | 1985-11-25 | 1986-01-02 | Biogen Nv | Enhanced secretion of heterologous proteins |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US6858598B1 (en) * | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US20070105887A1 (en) * | 2005-11-04 | 2007-05-10 | Wyeth | Antineoplastic combinations of temsirolimus and sunitinib malate |
| AU2007272330A1 (en) * | 2006-07-13 | 2008-01-17 | Zymogenetics, Inc. | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| WO2008057461A2 (en) * | 2006-11-02 | 2008-05-15 | Acceleron Pharma, Inc. | Alk1 receptor and ligand antagonists and uses thereof |
| US20090017019A1 (en) * | 2007-06-01 | 2009-01-15 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| KR20100090683A (ko) * | 2007-11-09 | 2010-08-16 | 제넨테크, 인크. | 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법 |
| EP2280960A1 (en) * | 2008-04-16 | 2011-02-09 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
| TWI586364B (zh) * | 2008-05-02 | 2017-06-11 | 艾西利羅製藥公司 | 調節血管新生與周圍細胞組成的方法與組合物 |
| US7998973B2 (en) * | 2009-11-13 | 2011-08-16 | Aveo Pharmaceuticals, Inc. | Tivozanib and temsirolimus in combination |
| US20120207671A1 (en) * | 2010-04-15 | 2012-08-16 | Vegenics Pty Limited | Combination treatment with vegf-c antagonists |
-
2013
- 2013-02-01 EP EP13744185.3A patent/EP2809335A4/en not_active Withdrawn
- 2013-02-01 US US13/757,672 patent/US20130202594A1/en not_active Abandoned
- 2013-02-01 CA CA2863188A patent/CA2863188A1/en not_active Abandoned
- 2013-02-01 RU RU2014134923A patent/RU2633638C2/ru not_active IP Right Cessation
- 2013-02-01 BR BR112014019151A patent/BR112014019151A2/pt not_active Application Discontinuation
- 2013-02-01 MX MX2014009277A patent/MX2014009277A/es unknown
- 2013-02-01 WO PCT/US2013/024510 patent/WO2013116781A1/en not_active Ceased
- 2013-02-01 KR KR1020147024468A patent/KR20140123558A/ko not_active Withdrawn
- 2013-02-01 JP JP2014555801A patent/JP2015506961A/ja active Pending
- 2013-02-01 AU AU2013214779A patent/AU2013214779A1/en not_active Abandoned
- 2013-02-01 CN CN201380013788.3A patent/CN104321070A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506961A5 (enExample) | ||
| Jiang et al. | cGAS-STING, an important pathway in cancer immunotherapy | |
| Harris et al. | Immuno-oncology combinations: raising the tail of the survival curve | |
| Procaccio et al. | Immunotherapy in gastrointestinal cancers | |
| Peters et al. | Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects | |
| Stern et al. | 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer | |
| JP2016539096A5 (enExample) | ||
| JP2018515474A5 (enExample) | ||
| RU2014134923A (ru) | Антагонисты alk1 и их применение в лечении почечно-клеточного рака | |
| JP2016187356A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| JP2016532693A5 (enExample) | ||
| JP2017506217A5 (enExample) | ||
| Duarte et al. | Gastric cancer: Basic aspects | |
| PH12012502193A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| WO2006038027A3 (en) | SINGLE DOMAIN ANTIBODIES AGAINST TNFRl AND METHODS OF USE THEREFOR | |
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| MX2021002190A (es) | Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20. | |
| MY191423A (en) | Binding molecules specific for cd73 and uses thereof | |
| JP2016537383A5 (enExample) | ||
| JP2016500251A5 (enExample) | ||
| EP2579895A4 (en) | ANTI-VEGF ANTIBODIES AND USES THEREOF | |
| JP2015512412A5 (enExample) | ||
| JP2017537972A5 (enExample) | ||
| JP2016502515A5 (enExample) |